A Phase 4 interventional study of Cetaphil in Plaque Psoriasis and Psoriasis, sponsored by Galderma R&D. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Psoriasis by Galderma Group AG — none open to participants now, none under way, none of them phase 3. Psoriasis · Galderma Group AG.
Among the 19 studies in Psoriasis by Galderma Group AG, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 10 in phase 4, and was the 19th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →None of the 19 studies in Psoriasis by Galderma Group AG is open now. The open studies under Psoriasis, anywhere →
Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 70 across the 18 interventional studies, 2,488 across the 1 observational. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Psoriasis by Galderma Group AG, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body. Evaluations of the regimen's efficacy will be conducted at 2 weeks, 4 weeks, and 8 weeks post-baseline.
This is a multi-center, open-label, in-use study. Adult subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will be recruited for participation in the study.
Subjects will report to the site at Baseline (day 0) visit, will be given an informed consent form, HIPAA form, photography release form, and medical history form to complete.
Subjects will be screened on the basis of the selection criteria for study qualification. Eligible subjects will be assessed at Baseline visit and instructed to start applying the skincare products to the assigned side of the body based on the pre-determined randomization.
Subjects to return to the site at Week 2 (± 3 days), Week 4 (± 5 days), and Week 8 (± 5 days) for follow-ups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will use topical skincare products to assigned side of the body, per randomization.
Drug: Cetaphil
Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.
Also known as: Topical Skincare Treatment
Change in Psoriatic Body Surface Area Compared to Baseline
Body Surface Area is a measure of how much skin is impacted by psoriasis using the following measurement.7 One handprint is equal approximately to 1% of Body Surface Area. A decrease in scores indicated an improvement.
Time frame: Baseline, Week 2, Week 4, Week 8
Change in Target Lesion Severity Compared to Baseline
Target lesion severity was measured by the Target Lesion Severity Score. Target Lesion Severity Score assessed erythema, induration, and scaling separately on a scale of 0-8, with 0 meaning no evidence of the parameter and 8 meaning very severe presence of the parameter. Target Lesion Severity Score was calculated as cumulative total of all 3 parameters, which a maximum score of 24 (8 x 3) and minimum score of 0. Total scale range is 0-24, where higher scores are worse outcomes. A decrease in scores indicated an improvement.
Time frame: Baseline, Week 2, Week 4, Week 8
Change of Physician Global Assessment Compared to Baseline
Physician Global Assessment assessed overall severity of psoriasis on a scale of 0 to 5, with 0 meaning no presence of psoriasis and 5 meaning very severe presence of psoriasis. A decrease in scores indicated an improvement.
Time frame: Baseline, Week 2, Week 4, Week 8
Change in Skin Scaliness Measured by Macroscopic Imaging
Macroscopic imaging was performed using Visioscan® VC 20plus to take an image of the target lesion. The Visioscan software was used to calculate the analyze the images for skin scaliness (a decrease in values indicates an improvement in roughness).
Time frame: Baseline, Week 2, Week 4, Week 8
Change in Skin Smoothness Measured by Macroscopic Imaging
Macroscopic imaging was performed using Visioscan® VC 20plus to take an image of the target lesion. The Visioscan software was used to calculate the analyze the images for skin smoothness (a decrease in values indicates an improvement in skin smoothness).
Time frame: Baseline, Week 2, Week 4, Week 8
Subject Treatment Satisfaction
Subjects were asked about their perception, satisfaction, and preference with each study treatment using a self-assessment questionnaire. Questionnaires were tabulated; and the number of all response options was reported for each question and time point. Favorable responses (i.e., strongly agree and agree, yes), neutral responses (i.e., neither agree nor disagree, no difference), and unfavorable responses (i.e., strongly disagree and disagree, no) were tabulated as appropriate. Number of participants with favorable responses was provided for each question.
Time frame: Week 2
Subject Treatment Satisfaction
Subjects were asked about their perception, satisfaction, and preference with each study treatment using a self-assessment questionnaire. Questionnaires were tabulated; and the number of all response options was reported for each question and time point. Favorable responses (i.e., strongly agree and agree, yes), neutral responses (i.e., neither agree nor disagree, no difference), and unfavorable responses (i.e., strongly disagree and disagree, no) were tabulated and reported as appropriate. Number of participants with favorable responses was provided for each question.
Time frame: Week 4
Subject Treatment Satisfaction
Subjects were asked about their perception, satisfaction, and preference with each study treatment using a self-assessment questionnaire. Questionnaires were tabulated; and the number of all response options was reported for each question and time point. Favorable responses (i.e., strongly agree and agree, yes), neutral responses (i.e., neither agree nor disagree, no difference), and unfavorable responses (i.e., strongly disagree and disagree, no) were tabulated and reported as appropriate. Number of participants with favorable responses was provided for each question.
Time frame: Week 8
Changes in Dryness Compared to Baseline [Tolerability Assessment]
Tolerability assessment was performed by the Investigator (parameter: dryness) using a 4-point analog scale (with half-point scores used as necessary to better describe the clinical condition). Investigator graded the degree of irritation of target lesion areas on a scale of 0 to 3, with 0 meaning parameter is not present, and 3 meaning parameter is severely present. A decrease in scores or lack of significant increase indicated tolerability/safety of the treatment products.
Time frame: Baseline, Week 2, Week 4, Week 8
Change in Burning/Stinging Compared to Baseline [Tolerability Assessment]
Tolerability assessment was performed by subjects (parameters: burning/stinging) using a 4-point analog scale (with half-point scores used as necessary to better describe the clinical condition). subjects graded the degree of irritation of target lesion areas on a scale of 0 to 3, with 0 meaning parameter is not present, and 3 meaning parameter is severely present. A decrease in scores or lack of significant increase indicated tolerability/safety of the treatment products.
Time frame: Baseline, Week 2, Week 4, Week 8
Change in Itching Compared to Baseline [Tolerability Assessment]
Tolerability assessment was performed by subjects (parameters: itching) using a 4-point analog scale (with half-point scores used as necessary to better describe the clinical condition). Subjects graded the degree of irritation of target lesion areas on a scale of 0 to 3, with 0 meaning parameter is not present, and 3 meaning parameter is severely present. A decrease in scores or lack of significant increase indicated tolerability/safety of the treatment products.
Time frame: Baseline, Week 2, Week 4, Week 8
Subject Quality of Life Satisfaction
Subjects were asked about their life quality by completing a Quality of Life questionnaire of 10 questions. Each question is scored from 0-3, with 0 being "not at all" or "not relevant" and 3 being "very much". All scores were summed to determine the Dermatology Quality of Life Index with score range 0-30: 0-1 (no effect at all on patient's life), 2-5 (small effect), 6-10 (moderate effect), 11-20 (very large effect), 21-30 (extremely large effect). A decrease in score totals from baseline to Week 8 indicated an improvement. A higher score indicates a greater impairment of quality of life.
Time frame: Baseline, Week 8
| Milestone | Skincare Product Treatment |
|---|---|
| Started | 46 |
| Completed | 41 |
| Not completed | 5 |
Body Surface Area is a measure of how much skin is impacted by psoriasis using the following measurement.7 One handprint is equal approximately to 1% of Body Surface Area. A decrease in scores indicated an improvement.
| BSA % | Skincare Product Treatment |
|---|---|
| Baseline | 9.3 ± 10.1 |
| Week 2 | 7.55 ± 6.89 |
| Week 4 | 7.49 ± 11.34 |
| Week 8 | 5.1 ± 5.55 |
Target lesion severity was measured by the Target Lesion Severity Score. Target Lesion Severity Score assessed erythema, induration, and scaling separately on a scale of 0-8, with 0 meaning no evidence of the parameter and 8 meaning very severe presence of the parameter. Target Lesion Severity Score was calculated as cumulative total of all 3 parameters, which a maximum score of 24 (8 x 3) and minimum score of 0. Total scale range is 0-24, where higher scores are worse outcomes. A decrease in scores indicated an improvement.
| Score on a scale | Skincare Product Treatment |
|---|---|
| Baseline | 10.85 ± 3.67 |
| Week 2 | 7.24 ± 3.59 |
| Week 4 | 5.34 ± 4.07 |
| Week 8 | 3.51 ± 3 |
Physician Global Assessment assessed overall severity of psoriasis on a scale of 0 to 5, with 0 meaning no presence of psoriasis and 5 meaning very severe presence of psoriasis. A decrease in scores indicated an improvement.
| Score on a scale | Skincare Product Treatment |
|---|---|
| Baseline | 2.67 ± 0.7 |
| Week 2 | 2.36 ± 0.79 |
| Week 4 | 1.73 ± 0.87 |
| Week 8 | 1.37 ± 0.83 |
Macroscopic imaging was performed using Visioscan® VC 20plus to take an image of the target lesion. The Visioscan software was used to calculate the analyze the images for skin scaliness (a decrease in values indicates an improvement in roughness).
| Pixels | Skincare Product Treatment |
|---|---|
| Baseline | 10.77 ± 4.92 |
| Week 2 | 6.78 ± 3.63 |
| Week 4 | 5.52 ± 4.26 |
| Week 8 | 5.71 ± 4.36 |
Macroscopic imaging was performed using Visioscan® VC 20plus to take an image of the target lesion. The Visioscan software was used to calculate the analyze the images for skin smoothness (a decrease in values indicates an improvement in skin smoothness).
| Pixels | Skincare Product Treatment |
|---|---|
| Baseline | 596.43 ± 192.39 |
| Week 2 | 394.49 ± 169.99 |
| Week 4 | 376.72 ± 205.51 |
| Week 8 | 353.95 ± 192.12 |
Subjects were asked about their perception, satisfaction, and preference with each study treatment using a self-assessment questionnaire. Questionnaires were tabulated; and the number of all response options was reported for each question and time point. Favorable responses (i.e., strongly agree and agree, yes), neutral responses (i.e., neither agree nor disagree, no difference), and unfavorable responses (i.e., strongly disagree and disagree, no) were tabulated as appropriate. Number of participants with favorable responses was provided for each question.
| Participants with favorable responses | Skincare Product Treatment |
|---|---|
| Subjects reported the cleanser left their skin feeling clean | 39 |
| Subjects reported the cleanser didn't irritate their skin | 38 |
| Subjects report this cleanser didn't dry their skin out | 40 |
| Subjects reported their skin felt nourished after using the regimen | 39 |
| Subjects reported it was easy to incorporate this skincare regimen into daily prescription routine | 40 |
| Subjects reported this moisturizer had helped the lesions feel softer | 40 |
| Subjects reported the skin lesions felt smoother since starting this moisturizer | 36 |
| Subjects reported their skin looked healthier since starting this moisturizer | 33 |
| Subjects reported the moisturizer kept their skin feeling hydrated throughout the day | 38 |
Subjects were asked about their life quality by completing a Quality of Life questionnaire of 10 questions. Each question is scored from 0-3, with 0 being "not at all" or "not relevant" and 3 being "very much". All scores were summed to determine the Dermatology Quality of Life Index with score range 0-30: 0-1 (no effect at all on patient's life), 2-5 (small effect), 6-10 (moderate effect), 11-20 (very large effect), 21-30 (extremely large effect). A decrease in score totals from baseline to Week 8 indicated an improvement. A higher score indicates a greater impairment of quality of life.
| Score on a scale | Skincare Product Treatment |
|---|---|
| Baseline | 9.24 ± 6.77 |
| Week 8 | 2.85 ± 3.17 |
Subjects were asked about their perception, satisfaction, and preference with each study treatment using a self-assessment questionnaire. Questionnaires were tabulated; and the number of all response options was reported for each question and time point. Favorable responses (i.e., strongly agree and agree, yes), neutral responses (i.e., neither agree nor disagree, no difference), and unfavorable responses (i.e., strongly disagree and disagree, no) were tabulated and reported as appropriate. Number of participants with favorable responses was provided for each question.
| Participants with favorable responses | Skincare Product Treatment |
|---|---|
| Subjects reported their skin was less dry and cracked | 36 |
| Subjects reported they worried less about their skin since starting the regimen | 34 |
| Subjects reported the products worked well with their prescription treatment as a complete regimen | 37 |
| Subjects reported this moisturizer helped smooth out their skin's rough texture | 39 |
| Subjects reported their skin appeared healthier-looking since starting this moisturizer | 38 |
| Subjects reported the skin lesions felt much softer since starting this moisturizer | 39 |
| Subjects reported this moisturizer had helped the lesions feel more hydrated | 40 |
| Subjects reported the skin lesions looked less flaky since starting this moisturizer | 39 |
Subjects were asked about their perception, satisfaction, and preference with each study treatment using a self-assessment questionnaire. Questionnaires were tabulated; and the number of all response options was reported for each question and time point. Favorable responses (i.e., strongly agree and agree, yes), neutral responses (i.e., neither agree nor disagree, no difference), and unfavorable responses (i.e., strongly disagree and disagree, no) were tabulated and reported as appropriate. Number of participants with favorable responses was provided for each question.
| Participants with favorable responses | Skincare Product Treatment |
|---|---|
| Subjects reported the cleanser was gentle for daily use on their psoriasis skin | 41 |
| Subjects reported the skin felt the least irritated since starting this skincare regimen | 34 |
| Subjects report their skin hadn't felt this great in a long time | 37 |
| Subjects reported this was thei favorite skincare regimen | 34 |
| Subjects reported this skincare regimen was the perfect choice as part of prescription regimen | 36 |
| Subjects reported their skin was at the healthiest-looking state since using this moisturizer | 37 |
| Subjects reported this moisturizer helped sooth my sensitive skin | 41 |
| Subjects reported they loved how soft their skin felt | 39 |
| Subjects reported the skin lesions had been consistently hydrated since using this moisturizer | 39 |
| Subjects reported this moisturizer helped smoothen out the rough, scaly lesions | 40 |
Tolerability assessment was performed by the Investigator (parameter: dryness) using a 4-point analog scale (with half-point scores used as necessary to better describe the clinical condition). Investigator graded the degree of irritation of target lesion areas on a scale of 0 to 3, with 0 meaning parameter is not present, and 3 meaning parameter is severely present. A decrease in scores or lack of significant increase indicated tolerability/safety of the treatment products.
| Score on a scale | Skincare Product Treatment |
|---|---|
| Baseline | 2.09 ± 0.72 |
| Week 2 | 1.38 ± 0.70 |
| Week 4 | 1.07 ± 0.98 |
| Week 8 | 0.71 ± 0.81 |
Tolerability assessment was performed by subjects (parameters: burning/stinging) using a 4-point analog scale (with half-point scores used as necessary to better describe the clinical condition). subjects graded the degree of irritation of target lesion areas on a scale of 0 to 3, with 0 meaning parameter is not present, and 3 meaning parameter is severely present. A decrease in scores or lack of significant increase indicated tolerability/safety of the treatment products.
| Score on a scale | Skincare Product Treatment |
|---|---|
| Baseline | 1.15 ± 1.05 |
| Week 2 | 0.67 ± 0.93 |
| Week 4 | 0.27 ± 0.67 |
| Week 8 | 0.12 ± 0.51 |
Tolerability assessment was performed by subjects (parameters: itching) using a 4-point analog scale (with half-point scores used as necessary to better describe the clinical condition). Subjects graded the degree of irritation of target lesion areas on a scale of 0 to 3, with 0 meaning parameter is not present, and 3 meaning parameter is severely present. A decrease in scores or lack of significant increase indicated tolerability/safety of the treatment products.
| Score on a scale | Skincare Product Treatment |
|---|---|
| Baseline | 2.04 ± 0.97 |
| Week 2 | 0.98 ± 0.98 |
| Week 4 | 0.68 ± 0.93 |
| Week 8 | 0.29 ± 0.64 |
Collected over 8 weeks (i.e., from the study start to the study completion).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Skincare Product Treatment | 0/46 (0%) | 0/46 (0%) | 4/46 (8.7%) |
| Event | Skincare Product Treatment |
|---|---|
| Burning/StingingSkin and subcutaneous tissue disorders | 3/46 |
| ItchySkin and subcutaneous tissue disorders | 1/46 |
| Age, Continuous(Years) | Skincare Product Treatment |
|---|---|
| Mean | 57.2 ± 15.9 |
| Sex: Female, Male(Participants) | Skincare Product Treatment |
|---|---|
| Female | 24 |
| Male | 22 |
| Race (NIH/OMB)(Participants) | Skincare Product Treatment |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 16 |
| White | 24 |
| More than one race | 5 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Skincare Product Treatment |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 41 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Skincare Product Treatment |
|---|---|
| United States | 46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2024 to primary completion in Jul 2024, 3 months.
Results were first posted in Jun 2026, 1 year 10 months after primary completion.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 3 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion